Pumping machine fault diagnosis based on fused RDC-RBF.

At present, the fault diagnosis of pumping units in major oil fields in China is time-consuming and inefficient, and there is no universal problem for high requirements of hardware resources. In this study, a fault fusion diagnosis method of pumping unit based on improved Fourier descriptor (IDF) and rapid density clustering RBF (RDC-RBF) neural network is proposed. Firstly, the minimum inertia axis of the center of gravity of the indicator diagram is obtained. The farthest point of the intersection of the inertial axis and the contour is determined as the starting point. Then Fourier transform is performed on the contour boundary of the graph to obtain the feature vector. Then, combining with the idea of fast density clustering algorithm, the number of hidden layer neurons of RBF is determined by finding the point with the highest density and using it as the hidden layer neuron. At the same time, the characteristics of Gaussian function are introduced to ensure the activity of hidden layer neurons. Finally, through dynamic adaptive cuckoo search (DACS), the step size is automatically adjusted according to the convergence speed of the objective function of RBF, and the efficiency and accuracy of RBF in different search stages are balanced. The optimal parameters such as the width and weight of RBF are determined, and the optimal RDC-RBF fault diagnosis model is established. The model is applied to the diagnosis of different fault types of pumping units, and compared with the current mainstream models. The average detection accuracy of the fusion RDC-RBF fault diagnosis method proposed in this paper reaches 96.3%. The measured results have high accuracy and short time. At the same time, this method is currently applied to oil production sites such as Shengli Oilfield in China, which greatly reduces the human resources required for fault diagnosis of pumping units in the past.

Improved intelligent clonal optimizer based on adaptive parameter strategy.

The intelligent clonal optimizer (ICO) is a new evolutionary algorithm, which adopts a new cloning and selection mechanism. In order to improve the performance of the algorithm, quasi-opposition-based and quasi-reflection-based learning strategy is applied according to the transition information from exploration to exploitation of ICO to speed up the convergence speed of ICO and enhance the diversity of the population. Furthermore, to avoid the stagnation of the optimal value update, an adaptive parameter method is designed. When the update of the optimal value falls into stagnation, it can adjust the parameter of controlling the exploration and exploitation in ICO to enhance the convergence rate of ICO and accuracy of the solution. At last, an improved intelligent chaotic clonal optimizer (IICO) based on adaptive parameter strategy is proposed. In this paper, twenty-seven benchmark functions, eight CEC 2104 test functions and three engineering optimization problems are used to verify the numerical optimization ability of IICO. Results of the proposed IICO are compared to ten similar meta-heuristic algorithms. The obtained results confirmed that the IICO exhibits competitive performance in convergence rate and accurate convergence.

Analysis of cardio-cerebrovascular adverse events in patients with brain metastasis from lung cancer treated with antiangiogenic drugs.

To observe the occurrence of cardio-cerebrovascular adverse events in patients with brain metastases from lung cancer treated with antiangiogenic drugs. A total of 182 patients with brain metastases from lung cancer were selected as the research objects. They were divided into patients receiving antiangiogenic drugs and those not receiving antiangiogenic drugs. The incidence of cardio-cerebrovascular adverse events was observed. The incidence of low-grade hypertension, cerebral haemorrhage, cerebrovascular accident, cerebrovascular arrhythmia and other cardio-cerebrovascular adverse events in patients with brain metastases from lung cancer after receiving antiangiogenic therapy was higher than in the group that did not receive anti-vascular therapy (P<0.05). The incidence of low-grade hypertension increased in patients with a previous history of hypertension after they received antiangiogenic drugs (P< 0.05). There were no statistically significant differences between cardio-cerebrovascular adverse event rates in patients treated with three different antiangiogenic drugs (P>0.05). Head radiotherapy did not increase the rate of cardio-cerebrovascular adverse events among patients treated with antiangiogenic drugs (P< 0.05), and the incidence of adverse events was lowest in the endost group combined with radiotherapy. The incidence of cardio-cerebrovascular adverse events in the combined gemcitabine + platinum (GP) and irinotecan + platinum (IP) regimen group was higher than that in the other combined chemotherapy regimen groups. Treatment of brain metastases from lung cancer using antiangiogenic drugs increases the incidence of low-grade cardio-cerebrovascular adverse events, but these drugs are safe and controllable and are worthy of clinical application.

A Software Deep Packet Inspection System for Network Traffic Analysis and Anomaly Detection.

In this paper, to solve the problem of detecting network anomalies, a method of forming a set of informative features formalizing the normal and anomalous behavior of the system on the basis of evaluating the Hurst (H) parameter of the network traffic has been proposed. Criteria to detect and prevent various types of network anomalies using the Three Sigma Rule and Hurst parameter have been defined. A rescaled range (RS) method to evaluate the Hurst parameter has been chosen. The practical value of the proposed method is conditioned by a set of the following factors: low time spent on calculations, short time required for monitoring, the possibility of self-training, as well as the possibility of observing a wide range of traffic types. For new DPI (Deep Packet Inspection) system implementation, algorithms for analyzing and captured traffic with protocol detection and determining statistical load parameters have been developed. In addition, algorithms that are responsible for flow regulation to ensure the QoS (Quality of Services) based on the conducted static analysis of flows and the proposed method of detection of anomalies using the parameter Hurst have been developed. We compared the proposed software DPI system with the existing SolarWinds Deep Packet Inspection for the possibility of network traffic anomaly detection and prevention. The created software components of the proposed DPI system increase the efficiency of using standard intrusion detection and prevention systems by identifying and taking into account new non-standard factors and dependencies. The use of the developed system in the IoT communication infrastructure will increase the level of information security and significantly reduce the risks of its loss.

An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving gene(s).

PURPOSE: To investigate the efficacy and safety of apatinib mesylate (AM) in treating advanced non-small cell lung cancer (aNSCLC) with wild or unknown epidermal growth factor receptor (w/nEGFR). METHODS: A total of 34 w/nEGFR -aNSCLC patients who failed chemotherapy from August 2015 to April 2017 were administered orally AM (425 mg/d) as primary treatment and observed their progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR), as well as related adverse events. RESULTS: Efficacy was evaluable in 30 cases, with median PFS (mPFS) 3.75 months (95% CI 0.648-6.852), ORR 20%, and DCR 73.33%. The main adverse reactions included hypertension (52.94%), hand-foot syndrome (52.94%), proteinuria (44.12%), and fatigue (41.18%); no drug-related death occurred. The efficacy correlation analysis showed that Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (p=0.008) combined with chemotherapy (p=0.009) were the factors that extended PFS, and combined chemotherapy (p=0.040, HR=3.052, 95% CI 1.052- 8.858) was an independent prognostic factor. CONCLUSIONS: AM has good therapeutic efficacy in treating aNSCLC patients after chemotherapy failure. The side effects can be controlled and it is worth testing it in large-scale clinical studies.

Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.

OBJECTIVE: The aim of this study was to evaluate the therapeutic efficacy and toxicity of a combination of tegafur-gimeracil-oteracil potassium capsules (S-1) with oxaliplatin for treatment of advanced or recurrent colorectal cancer. SUBJECTS AND METHODS: Between October 2009 and October 2011, 70 patients at our hospital with advanced or recurrent colorectal cancer were enrolled into our study and divided randomly into two groups: A treatment group (S-1 combined with oxaliplatin) and a control group (Xeloda combined with oxaliplatin). All patients received 130 mg/m(2) oxaliplatin by intravenous infusion on day 1, every three weeks. Patients in the treatment group were treated with oral administration of 30-40 mg/m(2) S-1 twice daily for 14 days. Patients in the control group were treated with oral administration of 1000 mg/m(2) Xeloda twice daily for 14 days. The efficacy and toxicity of the combination therapy were evaluated after two cycles of treatment. RESULTS: The response rates in the treatment and control groups were 54.3% and 42.9%, respectively. The disease control rates of the two groups were 80.0% and 74.3%, respectively. The 1-year and 2-year survival rates were 73.6% and 39.1% in the treatment group, respectively, compared to 73.8% and 37.8% in the control group. No statistical difference between the two groups for any of the parameters, including toxicity, was observed (P > 0.05). CONCLUSION: The efficacy of the S-1 and oxaliplatin combination regimen in advanced or recurrent colorectal cancer treatment is not inferior to the combination of Xeloda and oxaliplatin and does not result in additional toxicity. Therefore, S-1 could be used to substitute Xeloda in combined chemotherapy with oxaliplatin for the treatment of advanced or recurrent colorectal cancer.

Therapeutic regimens and prognostic factors of brain metastatic cancers.

OBJECTIVE: This work aims to investigate the therapeutic regimen of brain metastatic cancers and the relationship between clinical features and prognosis. METHODS: Clinical data of 184 patients with brain metastatic cancers were collected and analysed for the relationship between survival time and age, gender, primary diseases, quantity of brain metastatic foci, their position, extra cranial lesions, and therapeutic regimens. RESULTS: The average age of onset was 59.1 years old. The median survival time (MST) was 15.0 months, and the patients with breast cancer as the primary disease had the longest survival time. Females had a longer survival time than males. Patients with meningeal metastasis had extremely short survival time. Those with less than 3 brain metastatic foci survived longer than patients with more than 3. The MST of patients receiving radiotherapy only and the patients receiving chemotherapy only were all 10.0 months while the MST of patients receiving combination therapy was 16.0 months. Multiple COX regression analysis demonstrated that gender, primary diseases, and quantity of brain metastatic foci were independent prognostic factors for brain metastatic cancers. CONCLUSIONS: Chemotherapy is as important as radiotherapy in the treatment of brain metastatic cancer. Combination therapy is the best treatment mode. Male gender, brain metastatic cancers originating in the gastrointestinal tract, more than 3 metastatic foci, and involvement of meninges indicate a worse prognosis.

Genetic variant in CASP3 affects promoter activity and risk of esophageal squamous cell carcinoma.

Caspase-3 (CASP3) is the main executioner of apoptosis, mediating both extrinsic and intrinsic cell death signaling pathways, and is involved in tumor behaviors. In this study, we investigated the association of two regulatory variants in CASP3 and the risk of esophageal squamous cell carcinoma (ESCC) in 1026 cases and 1270 healthy controls. Odds ratios (OR) and 95% confidence intervals (CI) were computed by logistic regression. The function of the CASP3 829 A>C polymorphism was examined by luciferase reporter assay and real-time PCR. A significant increased risk of ESCC was found for the CASP3 829 AC and CC genotypes with OR (95% CI), 1.53 (1.26-1.89) and 1.42 (1.11-1.82), respectively. When stratified by age and gender, the risk of ESCC was more significant in younger (≤57 years) and male individuals. No significantly changed risk of ESCC was related to 20541 C>T variant. Luciferase reporter assay showed 829 A>C variant dramatically reduced the transcriptional activity of luciferase reporter gene by over 95% in both KYSE30 and KYSE450 esophageal cancer cells. Remarkably, the transcriptional activity of the 829C-containing construct was much lower than the activity of the pGL3-basic construct, with over 85% reduction in both cell lines. Real-time PCR analyses showed that 829 AA genotype carriers had significantly higher RNA levels (0.015 ± 0.00216, n = 24) than the 829 AC genotype carriers (0.00969 ± 0.00136, n = 36), and 829 CC genotype carriers (0.00663 ± 0.00097, n = 20). These findings suggest that CASP3 829 A>C polymorphism may highly affect the function of caspase-3 and play an important role in the development of ESCC in Chinese populations.

Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population.

BACKGROUND: Over-expression and increased activity of cyclooxygenase (COX)-2 induced by smoking has been implicated in the development of cancer. This study aimed to explore the interaction between smoking and functional polymorphisms of COX-2 in modulation of gastric cardia adenocarcinoma (GCA) risk. METHODS AND FINDINGS: Three COX-2 polymorphisms, including -1195G>A (rs689466), -765G>C (rs20417), and 587Gly>Arg (rs3218625), were genotyped in 357 GCA patients and 985 controls. In the multivariate logistic regression analysis, we found that the -1195AA, -765GC, and 587Arg/Arg genotypes were associated with increased risk of GCA (OR = 1.50, 95% CI = 1.05-2.13; OR = 2.06, 95% CI = 1.29-3.29 and OR = 1.67, 95% CI = 1.04-2.66, respectively). Haplotype association analysis showed that compared with G(-1195)-G(-765)- G(Gly587Arg), the A(-1195)-C(-765)-A(Gly587Arg) conferred an increased risk of GCA (OR = 2.49, 95% CI = 1.54-4.01). Moreover, significant multiplicative interactions were observed between smoking and these three polymorphisms of -1195G>A, -765G>C, and 587Gly>Arg, even after correction by false discovery rate (FDR) method for multiple comparisons (FDR-P(interaction) = 0.006, 5.239×10(-4) and 0.017, respectively). Similarly, haplotypes incorporating these three polymorphisms also showed significant interaction with smoking in the development of GCA (P for multiplicative interaction = 2.65×10(-6)). CONCLUSION: These findings indicated that the functional polymorphisms of COX-2, in interaction with smoking, may play a substantial role in the development of GCA.

Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer.

BACKGROUND & AIMS: Overexpression of cyclooxygenase-2 (COX-2) is implicated in many steps of cancer development. Single nucleotide polymorphisms (SNPs) in the COX-2 promoter might contribute to differential COX-2 expression and subsequent interindividual variability in susceptibility to cancer. This study sought to identify functional SNPs in the COX-2 promoter and evaluated their effects on the risk of developing esophageal squamous cell carcinoma (ESCC). METHODS: Thirty individual DNA samples were sequenced to search for SNPs, and the function of the SNPs was examined by a set of biochemical assays. Genotypes and haplotypes were analyzed in 1026 patients and 1270 controls, and odds ratios and 95% confidence intervals (CIs) were estimated by logistic regression. RESULTS: Three SNPs, -1290A-->G, -1195G-->A, and -765G-->C, were identified; the frequencies of variant alleles were 0.04, 0.51, and 0.02, respectively. The -1195G-->A change creates a c-MYB binding site and displays a higher promoter activity. The -1195A-containing haplotypes had significantly increased luciferase expression and COX-2 messenger RNA levels in esophageal tissues compared with the -1195G-containing counterparts. A case-control analysis showed a 1.72-fold (95% CI, 1.35-2.20) and 2.24-fold (95% CI, 1.59-3.16) excess risk of developing ESCC for the -1195AA or -765CC genotype carriers compared with noncarriers. A greater risk of developing ESCC was observed for A(-1195)-C(-765)-containing haplotypes compared with G(-1195)-G(-765)-containing haplotypes, suggesting an interaction between the -1195G-->A and -765G-->C polymorphisms in the context of haplotype. CONCLUSIONS: These findings indicate that genetic variants in COX-2 may play a role in mediating susceptibility to esophageal cancer.

[Hemostatic effects of Sorbalgon dressing after intranasal endoscopic surgery].

OBJECTIVE: To study the therapeutic effects of Sorbalgon dressing for hemostasis after intranasal endoscopic surgery. METHODS: Intranasal endoscopic surgery was performed in 50 patients with bilateral chronic nasosinusitis and nasal polyps, after which the hemostatic effect of Sorbalgon and Vaseline dressings and nasal cavity reaction were observed. RESULTS: Sorbalgon dressing resulted in milder nasal swelling and pain without obvious nasal hemorrhage and mucous membrane reaction, and the average time of nasal recovery was shorter in comparison with Vaseline dressing, which caused severe pain, obvious haemorrhage, and nasal mucous membrane swelling with prolonged nasal recovery. Three months after the operation, similar mucous membrane epithelialization was observed in the nasal cavity managed with the two dressings. CONCLUSION: Sorbalgon dressing has good hemostatic effect after intranasal endoscopic surgery.

[Preparation and application of monoclonal antibodies to recombinant human IFN alpha].

OBJECTIVE: To prepare and apply monoclonal antibodies (McAb) against recombinant human interferon alpha (rHu IFN-alpha). METHODS: Five cell lines (2E9, 4G1, 2A7, 2C9, 4G10) secreting McAbs against rHu IFN-alpha were established by hybridoma technique. RESULTS: All the cell lines secreted monoclonal antibodies stably. Functions of secreting antibodies of the five cell lines lasted for 6 months in BALB/c mice and 8 months in cell culture. The specificity of antibody was constant. The Ig subclasses of the McAbs were IgG1. Anti-IFN McAb affinity purification column was prepared by coupling the anti IFN-alpha McAb to Sepharose 4B. The combining rate reached was higher than 95%. CONCLUSIONS: The highest purification efficiency was obtained by using 4G10 column.